Project BioShield: Consistent financing, markets, indemnity for biodefense vaccine developers needed
WASHINGTON, DC (April 4, 2003): Biotechnology companies are well suited to address the modest commercial opportunities offered by creating safer, more effective and less costly vaccines for biodefense ...
SAN DIEGO - When President Bush signed Project BioShield into law in July, he said he was immediately making $5.6 billion available to counter such anticipated threats as smallpox genetically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results